Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H3.3K27M peptide vaccine and nivolumab in H3.3K27M-positive gliomas
NCT02960230Phase 2Completed
- Start
- Nov 2016
- Primary completion
- Dec 2023
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of histone H3.3-K27M neoantigen vaccine in diffuse intrinsic pontine glioma (DIPG), glioma and diffuse midline glioma (DMG). Started Nov 2016; status: completed.
02
Drugs
histone H3.3-K27M neoantigen vaccine
03
Conditions
diffuse intrinsic pontine glioma (DIPG)gliomadiffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT02960230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02960230.